Review article | 12 April 2022
The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates December 2020
Lars Jacob Stovner, Knut Hagen, Mattias Linde & Timothy J. Steiner
Consensus article | 11 June 2022
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update
Simona Sacco, Faisal Mohammad Amin, Messoud Ashina, Lars Bendtsen, Christina I. Deligianni, Raquel Gil-Gouveia, Zaza Katsarava, Antoinette MaassenVanDenBrink, Paolo Martelletti, Dimos-Dimitrios Mitsikostas, Raffaele Ornello, Uwe Reuter, Margarita Sanchez-del-Rio, Alexandra J. Sinclair, Gisela Terwindt, Derya Uluduz, Jan Versijpt & Christian Lampl
Review article | 10 June 2021
Migraine and neuroinflammation: the inflammasome perspective
Oguzhan Kursun, Muge Yemisci, Arn M. J. M. van den Maagdenberg & Hulya Karatas
Research article | 3 May 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, Carmelina Maria Costa, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Valentina Favoni, Giulia Pierangeli, Carlo Lovati, Marco Aguggia, Florindo d’Onofrio, Alberto Doretti, Paola Di Fiore, Cinzia Finocchi, Renata Rao, Francesco Bono, Angelo Ranieri, Maria Albanese, Sabina Cevoli & Piero Barbanti for the GARLIT Study Group
Review article | 14 July 2021
Comorbidities of primary headache disorders: a literature review with meta-analysis
Valeria Caponnetto, Manuela Deodato, Micaela Robotti, Maria Koutsokera, Valeria Pozzilli, Cristina Galati, Giovanna Nocera, Eleonora De Matteis, Gioacchino De Vanna, Emanuela Fellini, Gleni Halili, Daniele Martinelli, Gabriele Nalli, Serena Serratore, Irene Tramacere, Paolo Martelletti & Alberto Raggi On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)
Research article | 25 October 2021
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
Fenne Vandervorst, Laura Van Deun, Annelies Van Dycke, Koen Paemeleire, Uwe Reuter, Jean Schoenen & Jan Versijpt
Review article | 1 August 2022
Long COVID headache
Claudio Tana, Enrico Bentivegna, Soo-Jin Cho, Andrea M. Harriott, David GarcÃa-AzorÃn, Alejandro Labastida-Ramirez, Raffaele Ornello, Bianca Raffaelli, EloÃsa Rubio Beltrán, Ruth Ruscheweyh & Paolo Martelletti
Research article | 21 April 2021
Disability, quality of life, productivity impairment and employer costs of migraine in the workplace
Toshihiko Shimizu, Fumihiko Sakai, Hitoshi Miyake, Tomofumi Sone, Mitsuhiro Sato, Satoshi Tanabe, Yasuhiro Azuma & David W. Dodick
Short Report | 7 October 2021
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
Edoardo Caronna, Victor José Gallardo, Alicia Alpuente, Marta Torres-Ferrus & Patricia Pozo-Rosich
Research article | 3 January 2022
IL-17 crosses the blood-brain barrier to trigger neuroinflammation: a novel mechanism in nitroglycerin-induced chronic migraine
Hao Chen, Xueqian Tang, Jin Li, Bangyan Hu, Wenqin Yang, Meng Zhan, Tengyun Ma & Shijun Xu
Publication years: 2021-2022
Source: Web of Science, data collected: January 2024